The involvement of IGF-1R overexpression in the development, progression, metastasis, and therapy resistance of several malignancies, such as breast [3,4], prostate [5,6], pancreatic [7], and ovarian [8] cancers, is well documented in both preclinical and clinical studies. The gene discussed is IGF1R; the disease is cancer.